Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-CN-MONO tirzepatide monotherapy vs placebo in Chinese adults with type 2 diabetes
CTR20232036Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20232036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232036.